📰 Curated from The Washington Post
📖 Read full article→
FDA approves pancreatic cancer drug that extends patients’ lives - The Washington Post
Technology and ScienceBy Daniel Wu8/26/20261 min read
In trials, Revolution Medicines’ daraxonrasib nearly doubled average survival times for one of the deadliest cancers.
✨ Key Highlights
- The FDA has approved daraxonrasib, a new pancreatic cancer drug developed by Revolution Medicines, offering a treatment option for one of the deadliest forms of cancer.
- In clinical trials, the drug nearly doubled patients' average survival times when compared with standard treatment.
- Daraxonrasib is administered as a pill, taken in place of chemotherapy, which distinguishes it from conventional intravenous cancer therapies.
- The approval marks a significant development for pancreatic cancer patients, who historically have faced limited effective treatment options and poor survival outcomes.
The Food and Drug Administration has approved a new pancreatic cancer drug, a pill that nearly doubled patients average survival times for one of the deadliest cancers when taken instead of chemother